Inactive Instrument

Kawasumi Laboratories, Incorporated Stock price

Equities

7703

JP3225800006

Medical Equipment, Supplies & Distribution

Dynamic Chart
Sumitomo Bakelite Company Limited completed the acquisition of an additional 65.99% stake in Kawasumi Laboratories, Incorporated from a group of shareholders for ¥25.7 billion. CI
Sumitomo Bakelite Company Limited made an offer to acquire the remaining 76.95% stake in Kawasumi Laboratories, Incorporated from a group of shareholders for ¥27 billion. CI
Kawasumi Laboratories, Incorporated Reports Consolidated Earnings Results for Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020 CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 2, 2019; Provides Year End Dividend Guidance for the Year Ending March 31, 2020 CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Second Quarter of Fiscal 2020 and for the Year Ending March 31, 2020 CI
Sumitomo Bakelite Company Limited completed the acquisition of 20.8% stake in Kawasumi Laboratories, Incorporated. CI
Sumitomo Bakelite Company Limited executed a capital and business alliance agreement to acquire 20.76% stake in Kawasumi Laboratories, Incorporated. CI
Tranche Update on Kawasumi Laboratories, Incorporated's Equity Buyback Plan announced on August 9, 2018. CI
Kawasumi Laboratories, Incorporated's Equity Buyback announced on August 9, 2018 has expired with 1,200,000 shares for ¥860.4 million. CI
Kawasumi Laboratories, Incorporated announces an Equity Buyback for 1,300,000 shares, representing 5.96% for ¥932.1 million. CI
Kawasumi Laboratories, Incorporated authorizes a Buyback Plan. CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2018; Announces Dividend for the Year Ended March 31, 2018, Payable on June 22, 2018; Provides Earnings Guidance or the Year Ending March 31, 2019; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2019 CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Earnings and Dividend Guidance for the Year Ending March 31, 2018 CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Full Year of Fiscal Year Ending March 31, 2018 CI
Japanese Organization for Medical Device Development, Inc. announced that it has received ¥610 million in funding from Sumitomo Bakelite Company Limited, Kawasumi Laboratories, Incorporated CI
More news
Managers TitleAgeSince
President 61 08-04-30
Chief Tech/Sci/R&D Officer 62 85-03-31
Director/Board Member - -
Members of the board TitleAgeSince
President 61 08-04-30
Chief Tech/Sci/R&D Officer 62 85-03-31
Chairman 61 19-06-19
More insiders
Kawasumi Laboratories, Incorporated is a Japan-based company engaged in the manufacture and sale of medical equipment and products. The Company operates in two business segments. The Blood- and Blood Vessel-related segment is engaged in the manufacture and sale of blood bags, blood collecting kits, blood transfer sets and others. The Extracorporeal Circulation segment mainly provides dialyzers, blood circuits, arterial venous fistula (AVF) needles, blood filters, physiological saline, artificial heart lung circuits and others.
More about the company
  1. Stock
  2. Equities
  3. Stock Kawasumi Laboratories, Incorporated - Japan Exchange